Français
Español
English
Portuguese
In August, 57 pediatric consultants drafted a letter urging hospitals, clinics and the Irish government to get behind a ban on Teva products over the war in Gaza.
By Shula Rosen
Teva, Israel’s leading pharmaceutical company, is seeing a significant boost in its stock price and positive analyst coverage despite European calls to boycott the company.
The company’s stock price has risen 60% as of November from its low point in April 2025.
In the last week, the stock has jumped 8.1%, with a current market cap of $25.3 billion. Nine out of 10 analysts have positive ratings on the stock.
This upward trajectory for Teva comes despite European voices in the BDS movement calling to sanction Teva’s medicine.
The most strident calls have been in Ireland, where last August, 57 pediatric consultants drafted a letter to Children’s Health Ireland Chief Executive Lucy Nugent and Health Minister Jennifer Carroll MacNeill stating that “the ongoing humanitarian catastrophe in Gaza, which has been widely recognized as meeting the legal definition of genocide,” justifies halting the distribution of Teva products.
The letter went on to say that because Teva pays taxes to the Israeli government, it “directly funds the diplomatic and military resources employed by the Israeli government to carry out a genocide and silence dissent domestically and internationally.”
In an interview with The Irish Times, a Teva spokesman said, “Any boycott on Teva may impose a risk on the health and well-being of those patients, the health care systems we serve, our global workforce and their families.”
In addition to Ireland, anti-Israel BDS activists, including Giorgia Gusciglio, Europe coordinator for Boycott, Divestment and Sanctions campaigns at the Palestinian BDS National Committee, urged clinics, pharmacies, hospitals and consumers throughout Europe not to buy Teva medicine.
Meanwhile, Teva Pharmaceuticals is winning investor confidence, with analysts rating the stock positively and setting an average target price of $25.57—nearly 25% above its current level.
Jefferies’ Dennis Ding reaffirmed a “buy” rating and a $24 target, saying Teva’s projected $2.5 billion in 2027 sales for its movement-disorder drug Austedo should hold steady despite U.S. drug pricing pressures.
Teva earned the Economist Group’s EuroFinance Excellence Award for outstanding cash and working-capital management.
Do You Love Israel? Make a Donation - Show Your Support!
Donate to vital charities that help protect Israeli citizens and inspire millions around the world to support Israel too!
Now more than ever, Israel needs your help to fight and win the war -- including on the battlefield of public opinion.
Antisemitism, anti-Israel bias and boycotts are out of control. Israel's enemies are inciting terror and violence against innocent Israelis and Jews around the world. Help us fight back!
